Atwood & Palmer Inc. Sells 985 Shares of Gilead Sciences, Inc. $GILD

Atwood & Palmer Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 344,082 shares of the biopharmaceutical company’s stock after selling 985 shares during the period. Gilead Sciences accounts for 2.4% of Atwood & Palmer Inc.’s holdings, making the stock its 12th biggest position. Atwood & Palmer Inc.’s holdings in Gilead Sciences were worth $38,148,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in GILD. Brighton Jones LLC increased its position in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the period. Bison Wealth LLC bought a new position in Gilead Sciences during the 4th quarter worth $215,000. Toronto Dominion Bank increased its position in Gilead Sciences by 11.0% during the 4th quarter. Toronto Dominion Bank now owns 710,523 shares of the biopharmaceutical company’s stock worth $65,631,000 after buying an additional 70,551 shares during the period. Tema Etfs LLC bought a new position in Gilead Sciences during the 4th quarter worth $2,849,000. Finally, Strategic Global Advisors LLC increased its position in Gilead Sciences by 4.2% during the 4th quarter. Strategic Global Advisors LLC now owns 37,285 shares of the biopharmaceutical company’s stock worth $3,444,000 after buying an additional 1,490 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $114.55 on Monday. The stock’s 50-day simple moving average is $114.04 and its 200 day simple moving average is $110.08. The firm has a market capitalization of $142.13 billion, a PE ratio of 22.82, a price-to-earnings-growth ratio of 0.78 and a beta of 0.36. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a twelve month low of $81.57 and a twelve month high of $121.83.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. During the same period last year, the firm posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a research report on Tuesday, August 19th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a research report on Friday, July 25th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Royal Bank Of Canada increased their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a report on Friday, August 8th. Finally, Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $115.39.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the sale, the chief financial officer directly owned 160,110 shares of the company’s stock, valued at $18,977,838.30. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 76,500 shares of company stock valued at $8,765,395. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.